What is William Blair's Forecast for Medpace Q1 Earnings?

Medpace Holdings, Inc. (NASDAQ:MEDP - Free Report) - Analysts at William Blair increased their Q1 2025 earnings estimates for Medpace in a research note issued on Tuesday, February 11th. William Blair analyst M. Smock now anticipates that the company will post earnings per share of $3.11 for the quarter, up from their prior forecast of $2.92. William Blair has a "Outperform" rating on the stock. The consensus estimate for Medpace's current full-year earnings is $11.93 per share. William Blair also issued estimates for Medpace's Q2 2025 earnings at $3.09 EPS and FY2026 earnings at $13.89 EPS.

A number of other analysts have also recently commented on MEDP. Baird R W cut shares of Medpace from a "strong-buy" rating to a "hold" rating in a research note on Wednesday, October 23rd. Robert W. Baird increased their price objective on shares of Medpace from $354.00 to $362.00 and gave the company a "neutral" rating in a research report on Monday, January 27th. Finally, TD Cowen dropped their price objective on shares of Medpace from $413.00 to $372.00 and set a "buy" rating on the stock in a research report on Wednesday, October 23rd. Seven research analysts have rated the stock with a hold rating and five have given a buy rating to the company. According to data from MarketBeat, the company currently has a consensus rating of "Hold" and a consensus target price of $381.44.

Medpace Price Performance

MEDP stock traded up $0.60 during trading hours on Friday, reaching $340.77. The stock had a trading volume of 372,411 shares, compared to its average volume of 274,333. The stock has a market capitalization of $10.59 billion, a PE ratio of 29.84, a price-to-earnings-growth ratio of 1.85 and a beta of 1.36. The stock has a 50-day simple moving average of $343.26 and a 200 day simple moving average of $347.75. Medpace has a fifty-two week low of $302.01 and a fifty-two week high of $459.77.

Medpace (NASDAQ:MEDP - Get Free Report) last announced its quarterly earnings results on Monday, February 10th. The company reported $3.67 EPS for the quarter, beating analysts' consensus estimates of $2.96 by $0.71. Medpace had a net margin of 17.66% and a return on equity of 50.87%.

Hedge Funds Weigh In On Medpace

A number of hedge funds have recently bought and sold shares of the business. Centaurus Financial Inc. increased its position in Medpace by 2.0% during the third quarter. Centaurus Financial Inc. now owns 1,513 shares of the company's stock worth $505,000 after acquiring an additional 29 shares during the period. Lindbrook Capital LLC increased its position in Medpace by 27.6% during the fourth quarter. Lindbrook Capital LLC now owns 134 shares of the company's stock worth $45,000 after acquiring an additional 29 shares during the period. HBK Sorce Advisory LLC increased its position in Medpace by 0.5% during the fourth quarter. HBK Sorce Advisory LLC now owns 5,384 shares of the company's stock worth $1,789,000 after acquiring an additional 29 shares during the period. Assetmark Inc. increased its position in Medpace by 20.1% during the fourth quarter. Assetmark Inc. now owns 173 shares of the company's stock worth $57,000 after acquiring an additional 29 shares during the period. Finally, Proficio Capital Partners LLC increased its position in Medpace by 4.1% during the fourth quarter. Proficio Capital Partners LLC now owns 730 shares of the company's stock worth $243,000 after acquiring an additional 29 shares during the period. 77.98% of the stock is owned by institutional investors.

About Medpace

Medpace Holdings, Inc engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance.